Juno prices IPO; Bellicum soars

Cancer immunotherapy plays Juno Therapeutics Inc. (NASDAQ:JUNO) and Bellicum Pharmaceuticals Inc. (NASDAQ:BCLM) priced their upsized IPOs, with Bellicum gaining in first-day trading Thursday.

Juno priced above its proposed range at $24 and raised $264.6 million through the sale of 11 million shares, giving it a valuation of $1.9 billion. The company had said Tuesday it intended to sell 9.3 million shares at $21-$23. ...